0001209191-15-071559.txt : 20150921
0001209191-15-071559.hdr.sgml : 20150921
20150921132342
ACCESSION NUMBER: 0001209191-15-071559
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150918
FILED AS OF DATE: 20150921
DATE AS OF CHANGE: 20150921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001269021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-244-6864
MAIL ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dier Mardi
CENTRAL INDEX KEY: 0001574591
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35935
FILM NUMBER: 151116986
MAIL ADDRESS:
STREET 1: PORTOLA PHARMACEUTICALS, INC.
STREET 2: 270 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-09-18
0
0001269021
PORTOLA PHARMACEUTICALS INC
PTLA
0001574591
Dier Mardi
C/O PORTOLA PHARMACEUTICALS, INC.
270 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Executive VP and CFO
Common Stock
2015-09-18
4
M
0
2934
5.10
A
2934
D
Common Stock
2015-09-18
4
M
0
978
5.10
A
3912
D
Common Stock
2015-09-18
4
M
0
5000
9.00
A
8912
D
Common Stock
2015-09-18
4
S
0
8912
55.00
D
0
D
Stock Option (Right to Buy)
5.10
2015-09-18
4
M
0
2934
0.00
D
2009-02-25
2019-02-25
Common Stock
2934
0
D
Stock Option (Right to Buy)
5.10
2015-09-18
4
M
0
978
0.00
D
2009-06-09
2019-06-09
Common Stock
978
0
D
Stock Option
9.00
2015-09-18
4
M
0
5000
0.00
D
2010-02-24
2020-02-24
Common Stock
5000
0
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2015, as amended on May 11, 2015.
These shares were sold in a single transaction at a price of $55.000.
/s/ Mike Ouimette, as Attorney-In-Fact
2015-09-18